1. Home
  2. BGMS vs JAGX Comparison

BGMS vs JAGX Comparison

Compare BGMS & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BGMS

Bio Green Med Solution Inc.

HOLD

Current Price

$1.01

Market Cap

5.8M

Sector

N/A

ML Signal

HOLD

Logo Jaguar Health Inc.

JAGX

Jaguar Health Inc.

HOLD

Current Price

$3.94

Market Cap

5.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BGMS
JAGX
Founded
1996
2013
Country
Malaysia
United States
Employees
19
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.8M
5.0M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
BGMS
JAGX
Price
$1.01
$3.94
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$60.00
AVG Volume (30 Days)
61.6K
320.3K
Earning Date
05-08-2026
04-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
82.42
EPS
N/A
N/A
Revenue
N/A
$11,511,000.00
Revenue This Year
N/A
$61.58
Revenue Next Year
$80,482.35
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.73
$0.22
52 Week High
$6.70
$8.00

Technical Indicators

Market Signals
Indicator
BGMS
JAGX
Relative Strength Index (RSI) 51.32 63.47
Support Level $0.89 $1.12
Resistance Level $1.13 $8.00
Average True Range (ATR) 0.08 0.75
MACD 0.00 0.06
Stochastic Oscillator 50.00 47.82

Price Performance

Historical Comparison
BGMS
JAGX

About BGMS Bio Green Med Solution Inc.

Bio Green Med Solution Inc is engaged in the supply and trading of protective and fire safety equipment. The company distributes products such as fire extinguishers, foam systems, fire-resistant doors, personal protective equipment, and safety apparel. It also provides fire safety systems, including sprinkler systems, fire alarm systems, valves, and CO2 systems. The company operates across commercial, industrial, healthcare, and residential sectors, with a focus on distribution and compliance with applicable safety standards.

About JAGX Jaguar Health Inc.

Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.

Share on Social Networks: